Sign in

NCT06702072Recruiting

Change in Task-related Oxygen Uptake After EBV Treatment

Change in Task-related Oxygen Uptake After Bronchoscopic Lung Volume Reduction With Endobronchial Valves

Source: ClinicalTrials.gov · Last updated 29 Apr 2026

Brief summary (registry, in English)

Rationale: Bronchoscopic lung volume reduction using endobronchial valves (EBV) has emerged as a viable treatment option for eligible patients with severe emphysema. In all studies conducted so far, exercise capacity has only been measured using the 6-minute walk distance test (6MWT). It is known that patients with COPD frequently experience problems during ADL, which can lead to avoidance of or care dependency for performing certain tasks and have a significant social impact on their lives. Patients report that it is easier to perform ADLs after EBV treatment. Previously it was found that it was easier for patient to perform these activities after the EBV treatment. However, the physiological load during these ADLs has never been investigated before. Potentially, EBV treatment could improve the metabolic load and consequently symptom perception, thus enhancing the execution of ADLs, which is an important patient-centred outcome. However, this has not been investigated so far. Objective: To investigate the change in exercise physiology during daily activities after EBV treatment. Study design: Observational study in which the study population will be asked to perform some additional test during regular visits for the bronchoscopic lung volume reduction treatment with valves. Study population: Patients with emphysema who are scheduled for a bronchoscopic lung volume reduction treatment using endobronchial valves. Intervention: Not applicable Main study parameters: The change in task-related oxygen uptake measured with a mobile oxygen device during activities of daily life 6 months after EBV treatment.

Status (registry)
Recruiting
Study type
Observational
Enrollment
20 (estimated)
First submitted
20 Nov 2024
Start date
2 Jun 2025
Primary completion date
1 Aug 2028
Lead sponsor
University Medical Center Groningen
Diseases
COPD
NCT number
NCT06702072

What you commit to

  • Study type: Observational
  • Planned participants: 20
  • From 2 Jun 2025 to the primary completion date, 1 Aug 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • 1\) Patients who cannot perform ADL activities without the use of Long Term Oxygen Therapy (LTOT).

Who the study is looking for

  • Patient is scheduled for a bronchoscopic lung volume treatment using Pulmonx Zephyr Endobronchial Valves;
  • Patient read, understood and signed the Informed Consent Form.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
University Medical Center Groningen
Coordinator of this site? Confirm its status
GroningenNetherlandsRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.